Skip to main content
West Pharmaceutical Services8-K: Debt refinancing

West Pharmaceutical enters new $950 million credit facilities, refinancing $130 million outstanding debt

Source: Autobound Signal API · 51 signals tracked for West Pharmaceutical Services · updated

Get West Pharmaceutical Services' live signals in Claude or ChatGPT, or by API

AskWhat changed at West Pharmaceutical Services this week? Use Autobound signals for westpharma.com.

What happened

On October 26, 2026, West Pharmaceutical entered into a new credit agreement providing a $750 million revolving facility and a $200 million term loan, while terminating its 2019 agreement and repaying $130.0 million outstanding.

Source

SEC EDGAROct 26, 2026

Current report (Form 8-K)

West Pharmaceutical Services 8-K

Filing excerpt

The New Credit Agreement (i) has a five-year term from the Effective Date (subject to certain extension mechanics therein by which the Company may request maturity date extensions of the revolving credit facility), (ii) provides for revolving advances up to an aggregate principal amount of $750 million at any one time outstanding (subject to satisfaction of certain conditions at the time advances are made) and (iii) provides for a term loan advance on the Effective Date in an aggregate principal amount of $200 million

sec.gov/Archives/edgar/data/105770/000010577026000114/wst-20261026.htmRead the full source

Extracted by Autobound

From the Signal API record
Signal
8-K: Debt refinancing

What this signalsFilings often name leadership changes, deals and spending plans.

Form
8-K
Fiscal year end
10/26
Filed
Oct 26, 2026

The full record

From the Signal API record

Numbers

Dollar figure
$750M (revolving credit facility under the New Credit Agreement)

Details

CIK
105770
Accession number
0000105770-26-000114
Timeframe
Multi year
Filing year
2026
Why it matters
Capital available or pressure
Signal category
Financial

Topics and mentions

Vendors

  • Bank of America
  • N.A.

Vendors named

  • Bank of America, N.A.

Extraction

Confidence
High
Relevance
85%
Sentiment
Positive
Detected
Oct 27, 2026
signal_type
sec-8k
signal_subtype
debtRefinancing

Use this data

Get every 8-K signal for West Pharmaceutical Services and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at West Pharmaceutical Services this week?”

  2. Send it to your own tools

    The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/7f5f599c-2f1e-4dea-830c-4ca8e6c3cf6d returns this record as JSON. POST /v1/companies/enrich returns every signal for westpharma.com.

{
  "signal_id": "7f5f599c-2f1e-4dea-830c-4ca8e6c3cf6d",
  "signal_type": "sec-8k",
  "signal_subtype": "debtRefinancing",
  "detected_at": "2026-10-27T08:04:24.551+00:00",
  "company": {
    "name": "West Pharmaceutical Services",
    "domain": "westpharma.com"
  },
  "data": {
    "detail": "On October 26, 2026, West Pharmaceutical entered into a new credit agreement providing a $750 million revolving facility and a $200 million term loan, while terminating its 2019 agreement and repaying $130.0 million outstanding. Proceeds are intended for working capital, capital expenditures, acquisitions, and general corporate purposes, signaling available budget for vendor solutions and expansions.",
    "metrics": {
      "timeframe": "multi_year",
      "dollar_context": "revolving credit facility under the New Credit Agreement",
      "dollar_millions": 750
    },
    "summary": "West Pharmaceutical enters new $950 million credit facilities, refinancing $130 million outstanding debt",
    "excerpts": "The New Credit Agreement (i) has a five-year term from the Effective Date (subject to certain extension mechanics therein by which the Company may request maturity date extensions of the revolving credit facility), (ii) provides for revolving advances up to an aggregate principal amount of $750 million at any one time outstanding (subject to satisfaction of certain conditions at the time advances are made) and (iii) provides for a term loan advance on the Effective Date in an aggregate principal amount of $200 million",
    "relevance": 0.85,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/105770/000010577026000114/wst-20261026.htm",
    "filing_date": "2026-10-26",
    "filing_year": 2026,
    "fiscal_year_end": "10/26",
    "sales_relevance": "Capital available or pressure",
    "signal_category": "financial",
    "vendors_mentioned": [
      "Bank of America, N.A."
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.